GenAI Revenue Leveraging AKASA’s GenAI driven revenue cycle enhancements, position as a partner to health systems seeking measurable financial uplift, citing documented gains of approximately $3.1M in additional revenue per deployment and 4,270 quality indicators per 10,000 discharges.

Custom LLM Advantage Highlight the capability to build a tailored large language model for each health system to improve accuracy across mid-cycle workflows such as prior authorization, CDI, inpatient coding, and clinical denials appeals, addressing specific institutional nuance and competitive differentiation.

Healthcare Focus Emphasize strategic focus on the health system market with demonstrated real-world GenAI deployments (notably the Cleveland Clinic) and ongoing customer momentum, suggesting scale-up opportunities with large integrated delivery networks and regional health systems.

Funding and Validation Leverage strong investor backing and a substantial fundraising history to build credibility with prospective buyers, while aligning with CIO/CFO priorities around technology-enabled revenue integrity and cost-to-collect reductions.

Product Roadmap Position AKASA’s upcoming offerings such as AKASA CDI Optimizer and Authorization Advisor as targeted expansions within the revenue cycle AI suite, providing cross-sell or upsell opportunities to existing customers seeking end-to-end GenAI support.